Caring Brands, Inc. (NASDAQ:CABR) Short Interest Update

Caring Brands, Inc. (NASDAQ:CABR) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 18,964 shares, a decline of 45.7% from the April 15th total of 34,917 shares. Based on an average trading volume of 53,861 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company’s stock are sold short.

Institutional Investors Weigh In On Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC purchased a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned about 0.25% of Caring Brands as of its most recent filing with the Securities & Exchange Commission.

Caring Brands Price Performance

Shares of NASDAQ:CABR traded down $0.02 during midday trading on Monday, reaching $0.92. The company had a trading volume of 57,471 shares, compared to its average volume of 122,400. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 5.62. The company’s fifty day simple moving average is $1.04. The stock has a market cap of $8.38 million and a PE ratio of -2.49. Caring Brands has a one year low of $0.71 and a one year high of $5.35.

Caring Brands (NASDAQ:CABR) last released its earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings started coverage on Caring Brands in a research note on Monday, January 26th. They issued a “sell (e)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.